A leukemia expert discusses ongoing challenges in chronic lymphocytic leukemia treatment, and how to discuss risk stratification with a patient.
Case: A 70-Year-Old Woman with Newly Diagnosed Chronic Lymphocytic Leukemia
Initial Presentation:
Treatment:
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More
Investigating Beyond the First-Generation BTK Inhibitors in CLL
March 5th 2024In the first article of a 2-part series, Farrukh Awan, MD, discusses the current landscape of treatment for patients with chronic lymphocytic leukemia and what Burton tyrosine kinase inhibitors are having the most impact for these patients.
Read More